<SEC-DOCUMENT>0001178913-22-003493.txt : 20220922
<SEC-HEADER>0001178913-22-003493.hdr.sgml : 20220922
<ACCEPTANCE-DATETIME>20220922070016
ACCESSION NUMBER:		0001178913-22-003493
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220922
FILED AS OF DATE:		20220922
DATE AS OF CHANGE:		20220922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		221257813

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2228500.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 22.9.1.5075
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">
      <div style="text-align: center; line-height: 1.25;">Form 6-K</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">For the month of September 2022</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Commission File Number 000-30902</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">
      <div style="text-align: center; line-height: 1.25;">COMPUGEN LTD.</div>
    </div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <table cellspacing="0" cellpadding="0" id="z06af3642fd9349dea3947a2697df7cc6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">26&#160;Harokmim Street</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon 5885849, Israel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744; &#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744; &#160; &#160;&#160;</div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">On September 22, 2022, Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;)
      issued a letter to its shareholders (the &#8220;<font style="font-weight: bold;">Shareholder Letter</font>&#8221;). A copy of the Shareholder Letter is furnished as Exhibit 99.1 to this Report on
      Form 6-K.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">In the Shareholder Letter, the Company announced that it is seeing encouraging signals of anti-tumor activity in the fully enrolled cohort
      expansion dual and triple combination studies in platinum resistant ovarian cancer patients. The Company further announced that it is continuing to analyze the ovarian data and plans to submit it for presentation at a medical conference that will
      take place by the end of the year. The Company will decide on next steps for this indication as the data mature.</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">The information contained in this Report on Form 6-K (excluding Exhibit 99.1) is hereby incorporated by reference into the Company&#8217;s
        Registration Statement on Form F-3, File No. 333-240183.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="za072a5103b744b82b73e4aedefa83387" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">Exhibit</div>
            <div style="line-height: 1.25; font-weight: bold;"><u>Number</u></div>
          </td>
          <td style="width: 93%; vertical-align: top;">
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25; font-weight: bold;"><u>Description of Exhibit</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z68256d9f67f94e6c98313ba4379758d3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm"><u>99.1</u></a></div>
          </td>
          <td style="width: 93%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm"><u>Compugen Letter to
                  Shareholders dated September 22, 2022.</u></a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signatures</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zaea21e4b23184f038c01d75a41e1f47d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49.8%; vertical-align: bottom;" colspan="3">
            <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: middle;" colspan="4">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Date: September 22, 2022</div>
          </td>
          <td style="width: 4.02%; vertical-align: bottom;">
            <div style="line-height: 1.25;">By:&#160;</div>
          </td>
          <td style="width: 36.14%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Eran Ben Dor&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 9.64%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4.02%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 36.14%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Eran Ben Dor</div>
            <div style="line-height: 1.25;">General Counsel</div>
          </td>
          <td style="width: 9.64%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 22.9.1.5075
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div>
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
        <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
        </div>
        <div><br>
        </div>
        <br>
      </div>
      <img width="128" height="53" src="image0.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FOR IMMEDIATE RELEASE</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Compugen Letter to Shareholders</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">HOLON, ISRAEL, September 22, 2022 &#8211;&#8211;<u>Compugen Ltd.</u> (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, is pleased to issue the following letter to
      shareholders:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Dear Shareholders,</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">As we approach the Jewish New Year, I am taking this opportunity to provide you with an update of our progress since the publication of the second quarter 2022 financial results. In these challenging times for the
      economy, the financial markets and specifically the small cap biotech sector, I would like to remind you that the fundamentals of Compugen remain strong. We believe that this, along with our recent strategic decision to focus our clinical strategy,
      prioritizing indications, and combinations which we believe have the highest probability of success, and with a cash runway into the end of 2024, positions us well to deliver value to our shareholders.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Data gives confidence in the potential contribution of COM701 in driving immune responses</div>
    <div style="line-height: 1.25;">In selected tumor types we identified signals of anti-tumor activity and insights into the contribution of the components in overlapping indications. We believe these signals coupled with changes occurring in the tumor
      microenvironment, in some hard to treat, checkpoint non-responsive indications, support further evaluation with COM701.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Encouraging signals of anti-tumor activity in ovarian cancer patients</div>
    <div style="line-height: 1.25;">I am excited to share with you that we are seeing encouraging signals of anti-tumor activity in the fully enrolled cohort expansion dual and triple combination studies in platinum resistant ovarian cancer patients. One
      of the biggest unmet needs in cancer is addressing less inflamed tumors, which are less responsive to immunotherapy such as ovarian cancer, as well as MSS-CRC which I will allude to later. We are continuing to analyze the ovarian data and plan to
      submit it for presentation at a medical conference that will take place by the end of the year. As the data mature, we will decide on next steps for this indication.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">On track to present new COM701/nivolumab MSS-CRC data in Q4 2022</div>
    <div style="line-height: 1.25;">As mentioned, MSS-CRC is a challenging to treat, less inflamed tumor with no approved immunotherapy. We are on track to present new data from our COM701/nivolumab MSS-CRC study at a medical conference in the fourth
      quarter of this year, where we saw a modest improvement in response rates over standard of care, warranting further evaluation in a study assessing the triple combination of COM701/COM902/anti-PD-1 in this indication.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Insight driven refocused development strategy, optimizes probability of success</div>
    <div style="line-height: 1.25;">In our 2022 second quarter financial results, we announced our decision to end our broad Phase 1 program early to focus on triple combinations in two prioritized indications. We believe this is the right decision for
      Compugen to maximize value to its shareholders for the following reasons: it is expected to enable us to leverage our own potentially first-in-class, anti-PVRIG, COM701 and to switch to develop our own potentially best in class anti-TIGIT, COM902; it
      provides us with flexibility and the ability to move fast in indications we believe COM701 and COM902 combination will have an impact, and it is expected to extend our cash runway into the end of 2024. With renewed focus, we are on track to share the
      design and timelines of our three new studies, which are planned as an amendment of the existing COM701/COM902 cohort expansion study, in the fourth quarter of 2022. These include the evaluation of</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbb3972d8bd4f473a9cb24898962cc0dc">

        <tr>
          <td style="width: 21pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Triple blockade of PVRIG/TIGIT/PD-1 in metastatic 2L+ MSS CRC</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z869bdd3f12234911803318c238a4059c">

        <tr>
          <td style="width: 21pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Triple blockade of PVRIG/TIGIT/PD-1 in anti-PD-(L)1 treated NSCLC and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6adf5afe0f3c4e7eb9112b9fcebafe4e">

        <tr>
          <td style="width: 21pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Triple blockade of PVRIG/TIGIT/chemotherapy in anti-PD-(L)1 treated NSCLC</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">As mentioned previously, while the data from the ovarian cancer cohorts mature, we will decide on next steps for this indication.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Computational discovery engine continues to deliver</div>
    <div style="line-height: 1.25;">We continue to do ground-breaking research and progress our early-stage pipeline. We remain on track to provide more details in the fourth quarter of this year on the next candidate coming from our computational
      discovery engine, COM503. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. We believe and we are excited that we are the first to target this pathway
      with an antibody for cancer immunotherapy.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Cash runway to support operations through the end of 2024</div>
    <div style="line-height: 1.25; font-weight: bold;"><font style="font-weight: normal;">Our decision to conclude early our broad Phase 1 program and to focus on our triple combination approach in two prioritized indications, is expected to extend our
        cash runway to support operations through the end of 2024. Our balance sheet is solid with no debt.</font><br style="line-height: 1.25;">
      <br>
      TIGIT landscape and Compugen differentiation</div>
    <div style="line-height: 1.25;">TIGIT is a competitive space attracting substantial investment, which is testament to the promise of modulating this pathway to enhance antitumor immune responses. Despite recent readouts in the field, we continue to
      have conviction that TIGIT may have a role in cancer treatment&#160;due to our scientific breakthroughs and track record in this field and look forward to seeing the overall survival data from others in this space, expected in 2023. Importantly, I want to
      emphasize, that we believe that Compugen has a differentiated approach in this field. First, we are leading the way in targeting TIGIT in combination with PVRIG and PD-1 in the clinic. PVRIG blockade might be the missing link required for full DNAM-1
      pathway blockade and optimal anti-tumor immunity. Second, in contrast to Fc-active anti-TIGIT antibodies, our COM902 does not deplete major TIGIT expressing T and NK lymphocytes in patients, potentially maximizing its anti-tumor capacity. In
      addition, we believe that anti-TIGITs with low Fc effector function may also have safety benefits.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">In summary, with our focused differentiated clinical strategy, numerous anticipated upcoming data readouts and with cash flow expected to be sufficient through the end of 2024, we believe we are well positioned to
      provide shareholder value, maintain our leadership position in the DNAM-1 axis and advance our vision to both extend and improve the quality of life of cancer patients.</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">I am delighted that Alberto Sessa will join us as our new Chief Financial Officer on November 1, 2022. I look forward to working with Alberto and believe that his extensive experience and track record in delivering
      growth, will be invaluable as we accelerate towards achieving our strategic ambitions.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">I would like to thank you for your ongoing support and remind you again of my commitment to delivering value. I am optimistic about our future and look forward to updating you on our progress throughout the remainder of
      the year.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">To all those celebrating&#160;Rosh Hashanah&#160;this week, the Jewish New Year, I wish you a year of good health, happiness, and peace.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Sincerely,</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">Anat Cohen-Dayag</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Anat Cohen-Dayag, Ph.D.</div>
    <div style="line-height: 1.25;">President and Chief Executive Officer,</div>
    <div style="line-height: 1.25;">Compugen Ltd.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
    <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities
      Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as &#8220;&#8216;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221;
      &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain
      these identifying words. Forward-looking statements include, but are not limited to, statements regarding Compugen&#8217;s belief that the strong fundamentals of Compugen along with Compugen&#8217;s recent strategic decision to focus its clinical strategy and
      with a cash runway into the end of 2024, positions Compugen well to deliver value to its shareholders, maintain its leadership position in the DNAM-1 axis and advance its vision to both extend and improve the quality of life of cancer patients;
      statements regarding Compugen&#8217;s belief that signals of anti-tumor activity in selected tumor types coupled with changes occurring in the tumor microenvironment, support further evaluation with COM701 in some hard to treat, checkpoint non-responsive
      indications; statements regarding Compugen&#8217;s plan to submit ovarian data for presentation at a medical conference that will take place by the end of the year and Compugen&#8217;s plan to decide on next steps for this indication; statements regarding
      Compugen&#8217;s decision to end its broad Phase 1 program early to focus on triple combinations in two prioritized indications which Compugen believes is the right decision to maximize value to its shareholders as the expected outcomes of such decision;
      statements regarding the potential first-in-class and best-in-class capabilities; statements regarding Compugen&#8217;s plans to share the design and timelines of its three new studies and the related plan to amend the existing COM701/COM902 cohort
      expansion study; statements regarding Compugen&#8217;s plans to provide more details on COM503 in the fourth quarter of this year and Compugen&#8217;s belief that it is the first to target the relevant pathway with an antibody for cancer immunotherapy;
      statements regarding Compugen&#8217;s expectation that its decision to conclude early its broad Phase 1 program and to focus on its triple combination approach in two prioritized indications is expected to extend its cash runway to support operations
      through the end of 2024; statements regarding Compugen&#8217;s belief that TIGIT may have a role in cancer treatment&#160;due to its scientific breakthroughs; statements regarding Compugen's belief that it has a differentiated approach in the TIGIT field and
      the belief that PVRIG blockade might be the missing link required for full DNAM-1 pathway blockade and optimal anti-tumor immunity and that anti-TIGITs with low Fc effector function may also have safety benefits. These forward-looking statements
      involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking
      statements. Among these risks: the effect of the global COVID-19 pandemic may continue to negatively impact the global economy and may also adversely affect Compugen&#8217;s business; in the near term, Compugen is highly dependent on the success of COM701
      and of COM902; Compugen may not be able to advance its internal clinical stage programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either alone or with a collaborator, or
      may experience significant delays in doing so; Clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific
      product or may not be able to conduct or complete its trials on the timelines it expects; Compugen has limited experience in the development of therapeutic product candidates, and it may be unable to implement its business strategy given that
      Compugen&#8217;s approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; and Compugen does not know whether it will be able to discover and develop
      additional potential product candidates or products of commercial value. These risks and other risks are more fully discussed in the &#8220;Risk Factors&#8221; section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange
      Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied
      upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Investor Relations contact:</font><br>
      Yvonne Naughton, Ph.D.</div>
    <div style="line-height: 1.25;">Head of Investor Relations and Corporate Communications Compugen Ltd.</div>
    <div style="line-height: 1.25;">Email: <u>ir@cgen.com</u></div>
    <div style="line-height: 1.25;">Tel: +1 (628) 241-0071</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: Poppins, Poppins; font-size: 1pt;">&#160;</div>
    <div style="line-height: 1.25; font-family: Poppins, Poppins; font-size: 1pt;">&#160;
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ =P!2  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !O 1L# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $<F_RG\H+YF#MW=,]L^U>>OH?Q49V9?%^D("?NC3P0/;D9KLM?
MT*T\1Z/-I=\9A;S%2YAD*-P0PY'N*\2N+3X-6=S+;7&N:U%-$Q1T9KK*D=1]
MR@#NO[!^*W_0Y:3_ ."X?X4?V#\5O^ARTG_P7#_"N V?!3_H8=8_[[NO_B*-
MGP4_Z&'6/^^[K_XB@#LM6A^(NA:9-J6I^.]&MK.''F2OIPPN2 .@SR2!7E6J
MI'K.HS7][\6[5IY3EMD5PBCV"@  >PK<O(_@N;*;R]8U2Y<(2D+R7*K(1T&2
MAQD]ZXC^UOAW_P!"=K'_ (-/_L* +W]CV/\ T5FW_P"^;K_"OIWPI;QVGA'1
MX(KO[9&EG%MN02?.^4?/SSSU_&OE3^UOAW_T)VL?^#3_ .PKVGX6_%#P]J45
MOX9BM[C3&MXQ'9K>7'F>:.?E#8'(X 'ITZ4 >MT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56],\=G
M,]G;13W*J3''(^Q7;T+8./KBK5% 'GO_  E7Q _Z)DO_ (.H/\*/^$J^('_1
M,E_\'4'^%;GC#1KS5+6"6T\476@>03OEBV['!QPVX@9SC!_QKCO^$:U7_HL-
MQ^47_P 70!J_\)5\0/\ HF2_^#J#_"L?7M:^+%_!&-&\'+I4RMEV:_MKA7'I
M@@8/N#3_ /A&M5_Z+#<?E%_\71_PC6J_]%AN/RB_^+H YE]2^.2.4>+3T8=5
M9[,$?^/4W^U?CA_<TW_O[9__ !50>,OAWH312:[XC^(SW3(%C:1+9))",X P
MK9/6N&_X1_X9_P#0\ZA_X*6_QH ]\^'^N^-)GDLO&5A;*Q.Z&\@N8#D_W&1&
M)SZ$#ZUZ'7R38:1\.K+4+6[M_'6HB>"5)(\:2_W@01W]:^M1R : %HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***Y#6;SQ]]O9=#TG1?LB\![VZ?>_OA1A?S- &;XT\5^$)FFT#7;#4-0B1
ME:5(+25XPPZ#<N,D>U<5GX0?]"=JG_@#<?\ Q5=M]L^+'_0)\+?^!$U'VSXL
M?] GPM_X$34 <3GX0?\ 0G:I_P" -Q_\51GX0?\ 0G:I_P" -Q_\571ZAXP\
M=Z3,(=2D\"V4Q&1'<ZD\;$>N&(K"UOQCXTU2R^S6OBGP+IC$_--;:LI<CT!;
M./PYH Y?Q+?>"[62!/#GPWGO5*DS/=1W$>/0  Y/U^E8/]L6/_1)K?\ [ZNO
M\:Z#S_B#_P!%2\/?^#J/_P")K>T3PU\5M7DMYQX\M7TV1L/<VEV)_E'7;A0"
M?QH RO -C9>*/$\%N_PTM+"VB/FS74DEP!&!TQN."2>@_P *^C:IZ=9M8:?#
M:O=7%VT:@-/</NDD/J>WY"KE !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &?J6MZ3HJHVJ:G9V*R$A#<SK&&^FXC-
M<IXA\0^'M;MUM[;XBV>E(#\[6=[ ';_@3$X'TKG]7\8Z;JMZ9-0^%6O:BT>8
MXYI](#DKGMN&0#UQ5'^W/#G_ $175/\ P11_X4 6?L.A_P#1:M0_\&\%'V'0
M_P#HM6H?^#>"JW]N>'/^B*ZI_P""*/\ PH_MSPY_T175/_!%'_A0!'JLOA_2
M=/DO)/C#K5P$Z16FH1S2,?0*O\SQ7''XA: PP?&/Q$P1C[\'_P 74USJ_BC[
M5*;7X.:4MN7/E"7P[(7"YX#$<9QZ5%_:_C#_ *([HW_A.2_XT <S+_PK&>5I
M9KWQE)(QRSO#;DD_7=6QX<\'>"O%=Y]FT6#QI<MGYY/(MA''_O,6P*]+^'_A
M_4?$.Z\\2^!?"VE6*DJD/]D;+B0^N&)VK[D<_K7JUCI]EIEJMMI]I!:P*<B*
M",(H_ <4 >;:!\!O"6BWHNKG[3JC+]R*\*F,?50!G\>*]0C1(HUCC5411A54
M8 %/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQEC7MU% 'Q3_ ,*V\:_]"OJG_@.U?8F@:>ND>'=-TY5VBUM8X< =U4 UI44
#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
